Mottola Frank 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Feb 25, 2026
Insider Transaction Report
Form 4
Mottola Frank
SVP, Chief Tech. Ops. Officer
Transactions
- Award
Common Stock
2026-02-24+1,125→ 16,849 total - Tax Payment
Common Stock
[F1]2026-02-24$51.35/sh−603$30,964→ 16,246 total - Award
Common Stock
2026-02-24+750→ 16,996 total - Tax Payment
Common Stock
[F1]2026-02-24$50.86/sh−368$18,716→ 16,628 total - Award
Common Stock
2026-02-24+1,250→ 17,878 total - Tax Payment
Common Stock
[F1]2026-02-24$50.86/sh−670$34,076→ 17,208 total - Disposition to Issuer
Restricted Stock Unit
[F2][F3]2026-02-24−1,125→ 3,375 total→ Common Stock (1,125 underlying) - Disposition to Issuer
Restricted Stock Unit
[F2][F4]2026-02-24−750→ 0 total→ Common Stock (750 underlying) - Disposition to Issuer
Restricted Stock Unit
[F2][F5]2026-02-24−1,250→ 2,500 total→ Common Stock (1,250 underlying)
Footnotes (5)
- [F1]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
- [F2]Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- [F3]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
- [F4]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
- [F5]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Signature
/s/ Timothy C. Dec, as attorney-in-fact|2026-02-25